ArticleFrontiers in oncology2025
Case Report: Pathological diagnosis of left upper lobe nodules: two cases of composite small cell lung cancer and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Intestinal Obstruction Caused by Dual-Component Metastasis From Combined Small Cell Lung Cancer: A Rare Case and Literature Review.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined Small Cell Lung Cancer (C-SCLC) is defined by the World Health Organization (WHO) as a combination of Small Cell Lung Cancer (SCLC) and other components, which may include any type of Non-Small Cell Lung Cancer (NSCLC). It is a relatively rare type of lung cancer, with an incidence ranging from 2% to 28%, and its incidence is on the rise. We report two cases of combined small cell lung cancer (C-SCLC) diagnosed by postoperative pathology following thoracoscopic left upper lobectomy at our hospital. One case was small cell carcinoma combined with squamous cell carcinoma (95% SCLC + 5% SCC), while the other was small cell carcinoma combined with large cell carcinoma. Both patients were male with a history of heavy smoking. Postoperatively, they received adjuvant chemotherapy combined with immunotherapy and surgery alone, respectively. No recurrence was observed during follow-up. This paper, in conjunction with a literature review, discusses the clinical and pathological features, diagnosis, potential molecular markers, treatment, and prognosis of C-SCLC. We emphasize the importance of early surgical resection and individualized comprehensive treatment, aiming to provide clinical reference for the diagnosis and management of this rare type of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.